Nuveen LLC acquired a new stake in AVANOS MEDICAL, INC. (NYSE:AVNS - Free Report) in the 1st quarter, according to its most recent filing with the SEC. The fund acquired 128,365 shares of the company's stock, valued at approximately $1,839,000. Nuveen LLC owned 0.28% of AVANOS MEDICAL as of its most recent filing with the SEC.
Several other institutional investors and hedge funds have also modified their holdings of the business. State of Wyoming lifted its stake in AVANOS MEDICAL by 132.0% in the 4th quarter. State of Wyoming now owns 5,137 shares of the company's stock valued at $82,000 after acquiring an additional 2,923 shares in the last quarter. Tower Research Capital LLC TRC lifted its stake in AVANOS MEDICAL by 493.3% in the 4th quarter. Tower Research Capital LLC TRC now owns 8,075 shares of the company's stock valued at $129,000 after acquiring an additional 6,714 shares in the last quarter. EP Wealth Advisors LLC lifted its stake in AVANOS MEDICAL by 14.6% in the 4th quarter. EP Wealth Advisors LLC now owns 10,108 shares of the company's stock valued at $161,000 after acquiring an additional 1,289 shares in the last quarter. Heritage Family Offices LLP bought a new stake in AVANOS MEDICAL in the 1st quarter valued at approximately $146,000. Finally, Mariner LLC lifted its stake in AVANOS MEDICAL by 18.0% in the 4th quarter. Mariner LLC now owns 10,655 shares of the company's stock valued at $170,000 after acquiring an additional 1,625 shares in the last quarter. 95.17% of the stock is currently owned by institutional investors and hedge funds.
AVANOS MEDICAL Stock Performance
AVNS traded up $0.32 during trading hours on Thursday, reaching $12.67. The company's stock had a trading volume of 649,919 shares, compared to its average volume of 710,564. AVANOS MEDICAL, INC. has a 52 week low of $9.30 and a 52 week high of $25.36. The company's 50-day moving average is $11.62 and its 200-day moving average is $12.73. The company has a debt-to-equity ratio of 0.12, a quick ratio of 1.58 and a current ratio of 2.64. The firm has a market cap of $587.66 million, a PE ratio of -1.26 and a beta of 1.12.
AVANOS MEDICAL (NYSE:AVNS - Get Free Report) last posted its quarterly earnings results on Tuesday, August 5th. The company reported $0.17 earnings per share for the quarter, missing analysts' consensus estimates of $0.18 by ($0.01). AVANOS MEDICAL had a negative net margin of 66.89% and a positive return on equity of 6.16%. The business had revenue of $175.00 million during the quarter, compared to the consensus estimate of $165.50 million. During the same quarter last year, the company posted $0.34 EPS. AVANOS MEDICAL has set its FY 2025 guidance at 0.750-0.950 EPS. On average, equities analysts forecast that AVANOS MEDICAL, INC. will post 1.32 EPS for the current year.
Insiders Place Their Bets
In other news, Director Gary Blackford acquired 40,000 shares of the firm's stock in a transaction on Wednesday, August 13th. The shares were purchased at an average cost of $10.99 per share, with a total value of $439,600.00. Following the acquisition, the director directly owned 40,000 shares in the company, valued at $439,600. This represents a ∞ increase in their position. The purchase was disclosed in a document filed with the SEC, which is accessible through this link. Company insiders own 2.64% of the company's stock.
Analyst Ratings Changes
Several research firms have commented on AVNS. Zacks Research upgraded AVANOS MEDICAL to a "hold" rating in a research note on Tuesday, August 12th. Wall Street Zen cut AVANOS MEDICAL from a "strong-buy" rating to a "buy" rating in a research note on Saturday, August 9th. One equities research analyst has rated the stock with a Hold rating, According to MarketBeat, the company has an average rating of "Hold".
View Our Latest Analysis on AVANOS MEDICAL
AVANOS MEDICAL Company Profile
(
Free Report)
Avanos Medical, Inc, a medical technology company, offers medical device solutions in North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin America. It offers a portfolio of chronic care products that include digestive health products, such as Mic-Key enteral feeding tubes, Corpak patient feeding solutions, and NeoMed neonatal and pediatric feeding solutions.
See Also
Before you consider AVANOS MEDICAL, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AVANOS MEDICAL wasn't on the list.
While AVANOS MEDICAL currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
